Hologic (HOLX) Reports Q4 Earnings: What Key Metrics Have to Say

Core Viewpoint - Hologic reported a revenue increase of 4.5% year-over-year for the quarter ended September 2024, with earnings per share (EPS) of $1.01, slightly below analyst expectations [1] Financial Performance - Total revenue for the quarter was $987.9 million, exceeding the Zacks Consensus Estimate of $979.28 million by 0.88% [1] - EPS was reported at $1.01, compared to $0.89 in the same quarter last year, but fell short of the consensus estimate of $1.02 by 0.98% [1] Segment Performance - GYN Surgical revenue was $156.50 million, slightly below the average estimate of $156.71 million, with a year-over-year increase of 5.7% [3] - Molecular Diagnostics revenue reached $319.30 million, surpassing the average estimate of $302.56 million, reflecting a year-over-year growth of 9.4% [3] - Blood Screening revenue was $7.50 million, exceeding the estimate of $6.84 million, but showed a significant decline of 19.4% year-over-year [3] - Breast Imaging revenue was $293.40 million, slightly below the estimate of $298.18 million, with a year-over-year increase of 4% [3] - Total Diagnostics revenue was $443.30 million, exceeding the estimate of $429.35 million, with a year-over-year growth of 6.5% [3] - Skeletal Health revenue was $12.70 million, significantly below the estimate of $18.49 million, reflecting a decline of 54.6% year-over-year [3] - Cytology and Perinatal revenue was $116.50 million, slightly below the estimate of $119.95 million, with a year-over-year increase of 1.1% [3] - Total Breast Health revenue was $375.50 million, slightly above the estimate of $374.84 million, with a year-over-year growth of 6.4% [3] - Interventional Breast Solutions revenue was $82.10 million, exceeding the estimate of $76.66 million, with a year-over-year increase of 16.3% [3] - Service and other revenue was $200.10 million, surpassing the estimate of $188.59 million, reflecting a year-over-year growth of 6.3% [3] - Product Sales revenue was $787.80 million, slightly below the estimate of $790.58 million, with a year-over-year increase of 4.1% [3] Stock Performance - Hologic shares have returned 2.6% over the past month, outperforming the Zacks S&P 500 composite, which returned 0.4% [4] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [4]